{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:48:10Z","timestamp":1775227690368,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12185-024-03860-7","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T15:42:30Z","timestamp":1730302950000},"page":"126-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factor X consumption attenuates the coagulation effect of emicizumab: a case of severe hemophilia A treated with emicizumab and factor VIII-bypassing agents"],"prefix":"10.1007","volume":"121","author":[{"given":"Kuniyoshi","family":"Mizumachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3046-6915","authenticated-orcid":false,"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruto","family":"Shimonishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"issue":"1","key":"3860_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2516.2008.01931.x","volume":"15","author":"E Berntorp","year":"2009","unstructured":"Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009;15(1):3\u201310.","journal-title":"Haemophilia"},{"issue":"8","key":"3860_CR2","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","volume":"10","author":"M Hoffman","year":"2012","unstructured":"Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost. 2012;10(8):1478\u201385.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"3860_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/hae.12205","volume":"19","author":"A Shirahata","year":"2013","unstructured":"Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, et al. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics\/pharmacodynamics. Haemophilia. 2013;19(6):853\u201360.","journal-title":"Haemophilia"},{"issue":"1","key":"3860_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/hae.13050","volume":"23","author":"Y Shinkoda","year":"2017","unstructured":"Shinkoda Y, Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, et al. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors. Haemophilia. 2017;23(1):59\u201366.","journal-title":"Haemophilia"},{"issue":"4","key":"3860_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/bjh.14148","volume":"174","author":"K Nogami","year":"2016","unstructured":"Nogami K. The utility of thromboelastography in inherited and acquired bleeding disorders. Br J Haematol. 2016;174(4):503\u201314.","journal-title":"Br J Haematol"},{"issue":"7","key":"3860_CR6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/jth.14135","volume":"16","author":"K Nogami","year":"2018","unstructured":"Nogami K, Soeda T, Matsumoto T, Kawabe Y, Kitazawa T, Shima M. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. J Thromb Haemost. 2018;16(7):1383\u201390.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"3860_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","volume":"112","author":"K Ogiwara","year":"2020","unstructured":"Ogiwara K, Nogami K, Matsumoto N, Noguchi-Sasaki M, Hirata M, Soeda T, et al. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X. Int J Hematol. 2020;112(5):621\u201330.","journal-title":"Int J Hematol"},{"issue":"10","key":"3860_CR8","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2942","volume":"18","author":"T Kitazawa","year":"2012","unstructured":"Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570\u20134.","journal-title":"Nat Med"},{"issue":"7","key":"3860_CR9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1160\/TH17-01-0030","volume":"117","author":"T Kitazawa","year":"2017","unstructured":"Kitazawa T, Esaki K, Tachibana T, Ishii S, Soeda T, Muto A, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117(7):1348\u201357.","journal-title":"Thromb Haemost"},{"issue":"6","key":"3860_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1365-2516.2011.02498.x","volume":"17","author":"M Morfini","year":"2011","unstructured":"Morfini M, Bjerre J. Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia. Haemophilia. 2011;17(6):860\u20136.","journal-title":"Haemophilia"},{"issue":"3","key":"3860_CR11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","volume":"99","author":"DM Monroe","year":"1997","unstructured":"Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99(3):542\u20137.","journal-title":"Br J Haematol"},{"issue":"5","key":"3860_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.thromres.2009.12.010","volume":"125","author":"Y Nakatomi","year":"2010","unstructured":"Nakatomi Y, Nakashima T, Gokudan S, Miyazaki H, Tsuji M, Hanada-Dateki T, et al. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa\/FX mixture as an alternative bypassing agent. Thromb Res. 2010;125(5):457\u201363.","journal-title":"Thromb Res"},{"issue":"4","key":"3860_CR13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1160\/TH07-05-0367","volume":"98","author":"H Ostermann","year":"2007","unstructured":"Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P\/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007;98(4):790\u20137.","journal-title":"Thromb Haemost"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03860-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03860-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03860-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T15:51:55Z","timestamp":1737215515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03860-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3860"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03860-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.M. has no conflict of interest to disclose. Y.N. has received research grant from Takeda Pharmaceutical Co.. N.S. teaches a course endowed by CSL Behring. S.F. taught a course endowed by CSL Behring, and has received personal fees from Chugai Pharmaceutical Co., Ltd., CSL Behring, and Takeda Pharmaceutical Co.. K.O. taught a course endowed by CSL Behring and has received personal fees from Chugai Pharmaceutical Co., Ltd. and CSL Behring. M.T. has received personal fees from Chugai Pharmaceutical Co., Ltd. KM Biologics Co., Bayer AG, and CSL Behring. K.N. has received grants, personal fees, and non-financial support from Chugai Pharmaceutical Co., Ltd., personal fees from F. Hofmann-La Roche Ltd., grants, personal fees, and non-financial support from Sysmex Co. and Sekisui Medical, grants and personal fees from Takeda Pharmaceutical Co., grants and personal fees from Sanofi S.A, personal fees from CSL Behring Co., grants and personal fees from KM Biologics Co., grants and personal fees from Novo Nordisk A\/S, grants and personal fees from Bayer AG, grants and personal fees from Bioverativ Inc., and grants and personal fees from Shire Plc, personal fees from Fujimoto Seiyaku and is an inventor of the patents relating to emicizumab.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}